Brief: Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study

Pfizer

01/10/2026 07:42

Oct 1 (Reuters) - Pfizer Inc. PFE.N:
PFIZER'S TILREKIMIG SHOWS SIGNIFICANT SKIN CLEARANCE IN PHASE 2 ATOPIC DERMATITIS STUDY
PFIZER - PHASE 2 STUDY MEETS PRIMARY ENDPOINT WITH SIGNIFICANT EASI-75 IMPROVEMENT AT WEEK 16
PFIZER - TILREKIMIG WELL-TOLERATED WITH TEAE RATES COMPARABLE TO PLACEBO
PFIZER - 62.5% OF PATIENTS ON TILREKIMIG 450 MG Q2W ACHIEVE EASI-75 VERSUS 19.9% PLACEBO
PFIZER - NO SERIOUS ADVERSE EVENTS RELATED TO TILREKIMIG IN PHASE 2 STUDY
PFIZER - STAGE 2: UP TO 61% OF PATIENTS ON TILREKIMIG ACHIEVE EASI-75 VERSUS 9.1% PLACEBO
Source text: ID:nBw2fsQ7Va
Further company coverage: PFE.N

 ((Reuters.Briefs@thomsonreuters.com;))